{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"54","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"To determine the time to progression of asymptomatic multiple myeloma patients receiving TBL 12. The time to progression will be measured in units of a cycle (28 day cycles).\n\nProgression is defined using the International Uniform Response Criteria for Multiple Myeloma (Leukemia (2006)20:1467-1473). Which requires one or more of the following: \\>25% increase in SPEP (must also be an absolute increase of at least 5 g/dL), \\>25% increase in UPEP (must also be an absolute increase of at least 200 mg/24 hours), \\>25% increase in bone marrow plasma cells (must also be an absolute increase of at least 10%), new lytic bone lesions or soft tissue plasmacytomas, or development of hypercalcemia (not attributable to any other cause).","dispersionType":"Full Range","groups":[{"description":"TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression","id":"OG000","title":"TBL 12"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of treatment until the date of first documented progression","title":"Time to Progression","type":"PRIMARY","unitOfMeasure":"cycles"}